2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Tuberous Sclerosis
6
Seizures
5
Marijuana Abuse
3
Lennox Gastaut Syndrome
3
Epilepsies, Myoclonic
3
Colonic Neoplasms
3
Breast Neoplasms
3
Sturge-Weber Syndrome
2
Neoplasms
2
Nausea
2
Glioblastoma
2
Anxiety Disorders
2
Vomiting
1
Tuberous Sclerosis 2
1
Tuberous Sclerosis 1
1
Spasms, Infantile
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parasomnias
1
Pancreatic Neoplasms
1
Pain
1
Multiple Myeloma
1
Liver Neoplasms
1
Liver Cirrhosis
1
Gallbladder Neoplasms
1
Epilepsy
1
Dysgeusia
1
Drug Resistant Epilepsy
1
Colorectal Neoplasms
1
Interventions
Surveys and Questionnaires
5
Counseling
3
Motivational Interviewing
2
Interviews as Topic
2
College Fraternities and Sororities
2
Transportation
1
Spermine Synthase
1
Risk Factors
1
Risk Assessment
1
Riluzole
1
Price Transparency
1
Precision Medicine
1
Palliative Care
1
Methods
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
House Calls
1
Exercise
1
Ethanol
1
Educational Status
1
Decision Support Techniques
1
Cannabidiol
1
Blood Specimen Collection
1
Acceptance and Commitment Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Behavior
×
Cannabidiol
×
Clear all
NCT05864846
2026-04-27
EpiCom
Jazz Pharmaceuticals
Phase 4
Completed
79 enrolled